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Neonates have heightened susceptibility to infections. The biological mechanisms are
incompletely understood but thought to be related to age-specific adaptations in immunity
due to resource constraints during immune system development and growth. We present
here an extended analysis of our proteomics study of peripheral blood-plasma from a
study of healthy full-term newborns delivered vaginally, collected at the day of birth and on
day of life (DOL) 1, 3, or 7, to cover the first week of life. The plasma proteome was
characterized by LC-MS using our established 96-well plate format plasma proteomics
platform. We found increasing acute phase proteins and a reduction of respective
inhibitors on DOL1. Focusing on the complement system, we found increased plasma
concentrations of all major components of the classical complement pathway and the
membrane attack complex (MAC) from birth onward, except C7 which seems to have
near adult levels at birth. In contrast, components of the lectin and alternative complement
pathways mainly decreased. A comparison to whole blood messenger RNA (mRNA)
levels enabled characterization of mRNA and protein levels in parallel, and for 23 of the 30
monitored complement proteins, the whole blood transcript information by itself was not
reflective of the plasma protein levels or dynamics during the first week of life. Analysis oforg October 2020 | Volume 11 | Article 5785051
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Frontiers in Immunology | www.frontiersin.immunoglobulin (Ig) mRNA and protein levels revealed that IgM levels and synthesis
increased, while the plasma concentrations of maternally transferred IgG1-4 decreased in
accordance with their in vivo half-lives. The neonatal plasma ratio of IgG1 to IgG2-4 was
increased compared to adult values, demonstrating a highly efficient IgG1 transplacental
transfer process. Partial compensation for maternal IgG degradation was achieved by
endogenous synthesis of the IgG1 subtype which increased with DOL. The findings were
validated in a geographically distinct cohort, demonstrating a consistent developmental
trajectory of the newborn’s immune system over the first week of human life across
continents. Our findings indicate that the classical complement pathway is central for
newborn immunity and our approach to characterize the plasma proteome in parallel with
the transcriptome will provide crucial insight in immune ontogeny and inform new
approaches to prevent and treat diseases.Keywords: ontogeny, complement, innate immune system, immunoglobulin, proteomics, inhibitors, membrane
attack complex (MAC), terminal complement complex (SC5b-9)INTRODUCTION
Bacteria and viruses that cause mild to no disease in adults can be
life-threatening in newborns and infants (1). Neonatal infections
cause 700,000 annual casualties, corresponding to 40% of deaths in
children under 5 years of age (2). The biological mechanisms
responsible for the early age-specific susceptibility are thought to
be related to immune system development and age-specific
adaptations in immunity due to resource constraints (1–3). This
results in heightened vulnerability in early life where immune
protection primarily relies on the innate immune system
including leukocytes, cytokines, and the complement system, and
the added protection from maternal factors including IgG
antibodies transferred to the fetus over the placenta and IgA from
breast milk (4–6). The complement system is a central element in
the innate immune system and activation initiates several defense
mechanisms, including enhancing circulating immunoglobulins,
opsonization, immune cell recruitment, regulation of adaptive
immunity, and the direct disruption of cell membranes (5).
The developmental trajectory of the immune system is
increasingly recognized as a major determinant for overall health
throughout life (7). However, our knowledge of the early life
immune ontogeny and molecular mechanisms involved remains
limited. We recently published the most comprehensive systems
biology study of the first week of human life to date, using high-
dimensional analytic platforms (7). Systems biology studies,
including proteomics and transcriptomics, generate inherently
comprehensive data that can be analyzed on many levels. Herein
we present an extended analysis of the proteomics data of blood
plasma from newborns using an improved bioinformatic pipeline.
The high-dimensional molecular measurements together with
unbiased analytic approaches, enable a deep data-driven analysis.
The aim was to identify and characterize molecular networks and
signatures related to immune system changes during the first week
of life. Given the importance for newborn immunity, we focused
our analysis on the complement system and maternally
transferred antibodies.org 2This deep data analysis has greatly expanded on our original
findings, indicating a highly dynamic biological state during the
first week of life, compared to a relatively steady state in healthy
adults (8). Findings in our study’s main cohort fromWest Africa
(The Gambia) were validated in an independent cohort from
Australasia (Papua New Guinea, PNG). Even though dramatic
changes occur in the first week of life, ontogeny follows a robust
trajectory that is consistent even in geographically and ethnically
distinct populations.MATERIALS AND METHODS
Study Cohort and Ethics
Thirty and nineteen healthy, term newborns were enrolled at the
Medical Research Council (MRC) Unit The Gambia at London
School of Hygiene and Tropical Medicine and at the Institute for
Medical Research (IMR) in Goroka, Papua New Guinea in
accordance, with a local Ethics Committee-approved protocol
(MRC SCC 1436 and IMR IRB#1515 and MRAC #16.14). A
detailed description of the protocol has been published (9).
Following informed consent, mothers were screened for HIV-
I and -II and hepatitis B. Positivity for either virus represented an
exclusion criterion. Inclusion criteria were a healthy appearing
infant as determined by physical examination, born by vaginal
delivery at gestational age of >36 weeks, with a 5-min Apgar
score > 8, and a birth weight of >2.5 kg. Peripheral blood samples
were obtained from all infants on the day of birth (DOL0) and
then again either at DOL1, DOL3, or DOL7 to limit phlebotomy
to a maximum of twice in the first week of life (Figure 1 and
Supplementary Figure 1). Peripheral venous blood was drawn
from infants via sterile venipuncture directly into heparinized
collection tubes [Becton Dickinson (BD) Biosciences; San Jose,
CA, USA]. Aliquots (200 ml) were immediately placed in RNA-
later (Ambion Thermo Fisher; Waltham, MA, USA) for RNAseq
analysis with the remaining blood kept in the collection tubes at
room temperature. Within 4 h, the whole blood was centrifugedOctober 2020 | Volume 11 | Article 578505
Bennike et al. Ontogeny of Newborn Plasma Proteomeon site at 500 × g for 10 min at room temp and the plasma was
stored at −80°C. All samples were shipped on dry ice (World
Courier; New Hyde Park, NY, USA).
Plasma cytokine profiles were determined using a custom
designed multi-analyte Cytokine Human Magnetic Panel Bead
Array (Invitrogen/Life Technologies; Carlsbad, CA). Metabolite
profiles were determined by metabolomics (Metabolon, Durham,
NC, USA). Data was downloaded from the original publication
(7) and re-analyzed.
Proteomics Sample Preparation
For the original study (7), plasma samples from newborns were
prepared for proteome analysis using the in-house developed
plasma and serum proteomics workflow, based on the MStern
blotting sample processing and trypsinization protocol (10, 11).
To this end, 5 µL plasma were diluted in 100 µL sample buffer
(8 M urea in TRIS-HCl, pH 8.5). Protein disulfide bonds were
reduced with dithiothreitol (10 mM final concentration) and
alkylated with iodoacetamide (50 mM final concentration). An
aliquot with 10 µg protein was transferred to a 96 well plate with
a polyvinylidene fluoride (PVDF) membrane bottom
(MSIPS4510, Millipore, MA, USA). Protein digestion was
performed with sequencing-grade modified trypsin (V5111,
Promega, Madison, WI, USA) at a nominal protease to protein
ratio of 1:25 w/w. After incubation for 2 h at 37°C, the peptides
were eluted and concentrated to dryness in a vacuum centrifuge.
To monitor retention time stability and system performance, iRT
peptides (Biognosys, Schlieren, Switzerland) were spiked into
all samples.
Mass Spectrometry Analysis
The samples were analyzed using a nanoLC system (Eksigent,
Dublin, CA) equipped with a LCchip system (cHiPLC nanoflex,
Eksigent, CA, USA) coupled online to a Q Exactive Mass
Spectrometer (Thermo Scientific, Bremen, Germany). From each
sample, 0.2 µg peptide material was separated using a linear
gradient from 93% solvent A (0.1% formic acid in water), 7%
solvent B (0.1% formic acid in acetonitrile) which was increased to
32% solvent B over 60 min. The mass spectrometer was operatedFrontiers in Immunology | www.frontiersin.org 3in data-dependent mode, selecting up to the 12 most intense
precursors for fragmentation from each precursor scan.
Proteomics Data Analysis
Unbiased data-driven analytical approaches have the advantage
that the data can be repeatedly interrogated based on varying
starting hypotheses. Using the proteomics raw data from the
original study (7), we performed a label-free protein quantitation
(LFQ) analysis in the newest version of MaxQuant (v 1.6.2.5)
using standard settings with quantitation by razor (protein-
group shared) and unique peptides and LFQ normalization
(12). Proteins were identified using the built-in Andromeda
search engine and an updated reviewed UniProt Human
Reference Proteome (13). Standard search settings were
employed with matching between runs on and the following
abundant modifications: max three tryptic missed cleavages,
methionine oxidation as variable modification, and cysteine
carbamidomethylation as fixed modification (11). The revert
decoy search strategy in MaxQuant was used to filter all
reported proteins and peptides to <1% false discovery rate
(FDR) (14).
The lists of identified protein groups (henceforth referred to as
proteins) and relative protein LFQ quantities were imported into R
using Rstudio (15, 16), prior to application of an analytical
workflow beyond that commonly applied to proteomics. The
following additional filtering criteria were applied for quantifiable
proteins: removal of i) proteins, which are commonly introduced
during the handling, preparation and processing of the samples,
tagged as likely contaminants by MaxQuant (e.g., keratins, trypsin,
etc.), ii) proteins only identified by peptides containing variable
modifications, and iii) proteins that were quantifiable in less than
50% of DOL0 and DOL1, 3, or 7 study participants. The strict
filtering strategy enabled us to avoid the need to impute missing
datapoints, and only use actual data, except for conducting
principal component analysis (PCA) where missing values were
replaced with values from a Gaussian distribution (q = 0.01,
tune.sigma = 0.3) to simulate signals from low abundant proteins
(17). ComBat R-package was used to correct for batch effects for
samples run on different LC-MS columns and MStern plates (18).
Quantro R-package was used to analyze for global differences in the
protein abundances between the different DOLs (10,000
simulations), which could point to methodological problems
(19). Additionally, ggplot2 was used for visualizations, MixOmics
for analysis, and dplyr for data matrix formatting (20–22). All data
is publicly available and can be accessed through this publication.
The mass spectrometry RAW data and search results have been
deposited to the ProteomeXchange consortium via the PRIDE
partner repository and are available with the data set identifier
PXD019817, as well as archived on ImmPort (https://immport.
niaid.nih.gov/home) under accession numbers SDY1256 and
SDY1412 (23, 24).Differential Protein Expression Analysis
and Bioinformatics
We fitted a linear mixed-effects regression model of intensity,
with fixed effects of DOL, sex, LC column/MStern plate, and an = 10
n = 10
n = 10
n = 30
DOL0 DOL7DOL3DOL1
FIGURE 1 | Study design and number of enrolled newborns in the main
cohort enrolled in The Gambia.October 2020 | Volume 11 | Article 578505
Bennike et al. Ontogeny of Newborn Plasma Proteomerandom participant effect, using the lmer function from the lme4
R package (25). Proteins that were quantifiable in less than 50%
of DOL0 and DOL1, 3, or 7 study participants were removed,
and remaining missing values were not included in the analysis.
P-values and fold changes were calculated DOL-wise using the
paired experimental design, with a null-model without DOL
using the ANOVA-function, and we controlled the FDR by
applying the Benjamini–Hochberg correction method (26).
Proteins were considered to be significantly differentially
regulated at 5% FDR and +/− 0.2 log2 foldchange. Additionally,
we performed a missing-value analysis based on Fisher’s exact
testing on the data matrix prior to filtering, as the strict valid value
filtering scheme would have removed DOL-unique proteins.
Significant proteins were further analyzed using WebGestaltR
for pathway analysis, StringDB for obtaining protein-protein
interaction networks, and Cytoscape for visualization (27–29).
Boxplot center lines show the medians, box limits indicate the 25th
and 75th percentiles, whiskers extend 1.5 times the interquartile
range from the 25th and 75th percentiles, outliers are represented
by dots. FDR adjusted p-values (q-values) from the statistical
models are reported on the boxplots, unless otherwise stated.
Immunoglobulin G Subclass Ratio Analysis
The relative inter-abundances of the IgG subclasses were estimated
using the intensity-based absolute quantitation (iBAQ) values from
MaxQuant, calculated from unique peptide abundances only
(uploaded to the PRIDE repository PXD019817). To enable a
comparison to the adult state, we used data from a previously
published proteomics study of plasma from 30 healthy adult Danes
(10). To compensate for the different experimental designs, we
normalized the IgG ratios to IgG2 (of note, normalization to IgG3
yielded similar results) in each dataset. Significantly different Ig-
ratios were calculated using two-sample t-tests.
RNA Sample Preparation and Sequencing
For RNA sequencing, total RNA was extracted from whole blood
using the RiboPure RNA Purification Kit. Quantification and
quality assessment of total RNA was performed on an Agilent
2100 Bioanalyzer. Samples with sufficiently high RNA integrity
number were considered for sequencing. Poly-adenylated RNA
was captured using the NEBNext Poly(A) mRNA Magnetic
Isolation Module. Strand-specific cDNA libraries were
generated from poly-adenylated RNA using the KAPA
Stranded RNA-Seq Library Preparation Kit and sequenced on
a HiSeq 2500 (Illumina; San Diego, CA, USA). Sequence quality
was assessed using FastQC and MultiQC1.8.1 (30). The FASTQ
sequence reads were aligned to the human genome (Ensembl
GRCh38.98) using STAR v2.7 and mapped to Ensembl GRCh38
transcripts (31). Read-counts were generated using htseq-count
(HTSeq 0.11.2-1) (32). Data processing and subsequent
differential gene expression (DGE) analyses were performed
using the latest versions of R and DESeq2 using the Wald
statistics and paired analysis (33). Genes with very low counts
(with less than 10 counts in nine or more samples, or the smallest
number of biological replicates within each treatment group) and
globin transcripts were filtered out prior to DGE analysis.Frontiers in Immunology | www.frontiersin.org 4RESULTS AND DISCUSSION
Enrolled Participants
Blood samples were collected employing a sample-sparing
protocol, which enabled characterization of the plasma
proteome, plasma metabolome, cytokine/chemokine profile,
whole blood transcriptome, and single cell immunophenotype
in the same sample (7). We utilized a paired study design with a
blood sample collected from all newborns on the day of life
(DOL) 0, and a matching follow-up sample either at DOL1, 3, or
7 (Figure 1). The main cohort included 60 samples collected
from 30 newborns in The Gambia/West Africa and the smaller
validation cohort comprised 38 samples collected from 19
newborns in Papua New Guinea (PNG)/Australasia using a
similar experimental design (Supplementary Figure 1).
Having access to peripheral blood samples rather than cord
blood for the DOL0 sample, provided each subject with an ideal
specific baseline-sample. This would not have been the case with
cord-blood as differences between peripheral and cord-blood
have been reported (34). Findings in this study are limited to
healthy babies born by vaginal delivery.
Quantifiable Proteins in Newborn Blood
Plasma Cluster by Day of Life
We analyzed plasma samples using our published plasma
proteomics workflow in a 96-well plate format, and identified 382
plasma proteins (FDR<1%), of which 197 passed our criteria for
quantifiable proteins (10, 11). These numbers are comparable to
those reported in similar plasma- and serum studies (10, 35, 36).
Depletion of high-abundant proteins prior to analysis, such as
albumin, complement component proteins, and immunoglobulins,
could increase the number of monitored plasma proteins (10), but
could also interfere with the abundance of other proteins, since e.g.,
albumin functions as a protein carrier (37). Therefore, to ensure the
highest quality of data, we chose not to deplete the high-abundant
plasma-proteins prior to proteomics analysis, which also enables us
to characterize the levels of these, many of which are involved in
modulating the immune system, and were as such relevant to
our study.
Principal component analysis (PCA) of quantifiable proteins
in newborn blood plasma revealed consistent changes over the
first week in both the main cohort (Figure 2) and the validation
cohort (Supplementary Figure 2), demonstrating a common
developmental trajectory of the newborn plasma proteome
during the first week of life across continents.
The Number of Changed Plasma-Proteins
Increases With Age
This study aimed to identify differentiating proteins over the first
week of life. For this purpose, we performed a linear regression
analysis of the protein abundance data. Our statistical model
allowed us to identify an increasing number of proteins that showed
statistically significant DOL-dependent abundance differences
(Figures 3A, B, Supplementary Tables 1–3). A similar trajectory
was seen in the validation cohort (Supplementary Figures 3-5,
Supplementary Tables 4–6).October 2020 | Volume 11 | Article 578505
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sensitivity compared to analysis using t-tests, as evidenced by
identification of twice the number of differentiating proteins (7),
likely by achieving higher statistical power (38, 39).
The proteins with the largest abundance increase at DOL1
compared to DOL0 were the acute phase proteins haptoglobin
(HP) and serum amyloid A-1 (SAA1) (Figures 3C, D). SAA2 was
also increased but did not pass multiple hypothesis testing (q-value:
0.11, p-value 0.03) (Supplementary Table 7). HP, SAA1, and SAA2
were the top three most increased proteins in the validation cohort
at DOL1 when disregarding statistical significance as the number of
samples in the validation cohort was smaller (Supplementary Table
8). This demonstrates a consistent observation across geographically
distinct cohorts and experiments.
A correlation analysis of all protein level change relative to DOL0
(Figure 4) revealed several clusters of proteins with similar
trajectories, including a hemoglobin (Hb) cluster and an acute
phase response cluster with SAA1, SAA2, and complement
component C6. The expression of the various globin genes
is strictly balanced and coordinated, and the positive correlation
of the Hb subunits is expected and validates the applied
methodology (40).
Low Levels of Haptoglobin in the Hours
After Birth
Several studies have failed to consistently measure HP in
neonates and in particular at birth when concentrations are
low, likely because of insufficient assay sensitivity (41). The
reliable identification of HP at DOL0 demonstrates the high
sensitivity of the applied methodology. The finding of increased
HP after birth is in agreement with previous studies, where a
significant increase in HP was measured at DOL2-4 compared to
DOL0 (41), and in adults compared to neonates and children
(42). Our study demonstrates that the increased HP can be
measured as early as 24 h after birth.Frontiers in Immunology | www.frontiersin.org 5The main physiological function of HP is to sequester free
(extracellular) hemoglobin (Hb) released from destroyed red
blood cells (43). The HP-Hb complex is quickly cleared from
the circulation through monocytes and tissue macrophages via
CD163 receptors, and degraded in lysosomes rather than being
recycled which can lead to HP depletion (44). The gradual
increase of HP at DOL1, 3, and 7 relative to DOL0, may reflect
a physiologic rise of HP in neonatal plasma levels in these healthy
newborn cohorts, preceding the need for clearance of the fetal
hemoglobin HbF (a2g2) from the neonatal circulation as it is
gradually replaced by the adult type HbA (a2b2) over the first
6 months of life.
By binding excessive free Hb, HP exerts anti-inflammatory
and anti-oxidant effects (43). Newborns and infants with a
bacterial infection have increased HP-levels, and HP appears to
regulate some adverse effects of inflammation (41) but the role of
HP in neonatal sepsis is not yet fully understood. A study with a
higher time-resolution could provide additional insights into the
perinatal physiologic fluctuations of HP.
Acute Phase Response Proteins
Transiently Increase on Day of Life 1
SAA1 is an acute phase protein with antimicrobial activity (45)
mainly produced in response to infections (46), and was
significantly increased at DOL1 and returned to DOL0 levels at
DOL3 and DOL7.
SAA1 is mainly synthesized in the liver, but can also be
synthesized by stimulated monocytes and monocyte-derived
macrophages (47). We were unable to identify the corresponding
mRNA in the whole blood, which indicated that during the first
week of life SAA synthesis might be limited to the hepatocytes
rather than stimulated immune cells in circulation.
Increased SAA1-levels could indicate the presence of an acute
phase response at DOL1. To identify proteins with a similar
trajectory, we performed a correlation analysis of SAA1 against all
proteins (Table 1). Most proteins correlating positively with SAA1
were involved in the acute phase response. The protein with the
most negative correlation to SAA1, alpha-2-macroglobulin (A2M),
is involved in inhibiting the complement system response.
Additionally, clusterin (CLU), another central inhibitor of the
complement cascades, correlated negatively with SAA1.
Altogether these findings demonstrate the presence of an acute-
phase response 24 h after birth, driven by an increase of several
acute-phase proteins and a simultaneous reduction of inhibitory
proteins. Our findings are in line with a previous publication, where
SAA1 levels in newborns in Sweden were increased at DOL1 and
subsequently decreased at DOL2 and DOL3 (48), and an acute
phase response was evident shortly after birth (49, 50). Our study
further expands on the molecular mediators of the acute phase
response, demonstrating the involvement of the complement
system and simultaneous reduction of inhibitors. The relatively
short in vivo half-life of SAA1 (51, 52) in the 90-min range makes it
unlikely that the increase on DOL1 was directly caused by immune
cell activation during vaginal delivery. This is supported by the lack
of corresponding whole blood mRNA, indicating that hepatocytes
rather than activated immune cells are the likely point of synthesis.FIGURE 2 | Principal component analysis (PCA) plot of all quantifiable
proteins separates samples by day of life (DOL). PC, principal component.
Explained variance given in percentages.October 2020 | Volume 11 | Article 578505
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synthesis (53), and of adrenal gland production of cortisol, a
metabolite that enhances the acute phase response in part via
increasing IL-6 receptor expression on hepatocytes (18). To
further characterize molecular drivers of the acute phase response
in early life, we investigated plasma IL-6 and cortisol concentrations,
as determined by multi-plex assay and metabolomics, respectively.
Likely reflecting recent labor (50), both IL-6 and cortisol levels were
highest at DOL0 (7) (Supplementary Table 9), and likely initiate
the subsequent physiologic acute phase response of the newborn
(18, 50). Altered neonatal blood circulation and increased oxygen
levels, as well as decreasing levels of circulating maternal factors in
the newborn may also contribute to these early proteomic shifts.
Speculatively, this first newborn inflammatory acute phase response
could be a means of immune system development activation, in
response to the extrauterine transition and anticipation of
encounters with various microorganisms.
Complement System Development Is
Central Over the First Week of Life
To identify underlying biological themes in addition to the early
acute phase response, we performed a protein-protein interaction
analysis of the increasing number of proteins showing ontogenicFrontiers in Immunology | www.frontiersin.org 6changes during the first week of life. The analysis revealed that
many of the differentiating proteins were functionally related, and
especially a cluster of proteins involved in the complement system
increased with DOL (Figure 5, boxed area).
Activation of the complement system through the classical,
lectin, or alternative complement pathways culminates in the
common terminal pathway, which results in the formation of the
membrane-lysing pore-structure termed the membrane attack
complex (MAC) also known as the terminal component complex
(TCC) (Figure 6) (54).
Although several studies have investigated circulating
complement components in neonates (5), each of them have only
partially characterized the complement system. Our study represents
the first to characterize the development of the circulating
complement system trajectories as a whole over the first week of
life in two independent cohorts (Table 2, Supplementary Table 9)
including whole blood transcriptomics. Neonates are relatively
deficient in complement components, which increases their
susceptibility to infections during the first months of life (5). The
current consensus is that complement components are not able to
cross the placental membrane under physiological conditions, and
that all complement proteins identified in newborn blood therefore
are synthesized by the fetus/newborn, and mainly by hepatocytesA B
DC
FIGURE 3 | Differentially abundant plasma proteins (q-value < 0.05) compared to day of life (DOL) 0. (A) We identified a robust trajectory of differentially expressed
proteins over the first week of life. (B) Overlap of regulated proteins. Protein regulations of (C) Haptoglobin (HP). (D) Serum amyloid A1 (SAA1) normalized to DOL0,
with mean abundance difference indicated by dots connected with a line. q-value * <0.05, **: <0.01, ***: <0.001.October 2020 | Volume 11 | Article 578505
Bennike et al. Ontogeny of Newborn Plasma Proteome(55). It should be noted that C3 and C7 may be transferred from the
fetus to the mother, while C1RL may be a tissue (placenta) leakage
protein detected in newborn plasma (56).
The Classical Complement Pathway
Components Increase Over the First
Week of Life
The classical pathway is activated, primarily on mucosal surfaces,
by binding of the C1 complex (C1q, C1r, and C1s) to surface‐
bound immune complexes, mainly IgG or IgM (57). C1 activationFrontiers in Immunology | www.frontiersin.org 7initiates the terminal pathway and the formation of the MAC
transmembrane pore-structure on the target membrane.
We identified C1q (chains A, B, and C), C1r, C1s, C4 (isotype B),
and C2 components. While the data sufficed for the identification
of C1q chain A, they did not meet our stringent requirements for
robust quantification, i.e., quantitative analysis of C1qA was
omitted. Plasma concentrations of the C1 complex (C1qB, C1qC,
C1r, and C1s), C4B, and C2 from the classical component pathway
increased over the first week of life (Figure 7A, Table 2). C1r and
C1s were significantly increased on DOL3, and C1qB on DOL7FIGURE 4 | Clustered Pearson’s protein-protein correlation matrix of protein changes during the first week of life, of all quantifiable proteins (on the x- and y-axis)
which allows for identifying proteins with similar trajectories across all samples. Several clusters of correlating proteins were identified, including a cluster centered
around hemoglobin and an acute phase response cluster including SAA1 and SAA2.TABLE 1 | Proteins with abundance differences significantly correlating (p-value < 0.05) with serum amyloid A-1 protein (SAA1) demonstrated an acute-phase response
at DOL1.
R P-value Protein name Gene name Description UPID
1.000 <2.2E−16 Serum amyloid A-1 protein SAA1 Acute-phase response P0DJI8
0.821 5.78E−04 Serum amyloid A-2 protein SAA2 Acute-phase response P0DJI9
0.672 3.16E−03 Leucine-rich alpha-2-glycoprotein LRG1 Brown fat cell differentiation/bacterial response P02750
0.642 3.06E−04 Serum amyloid P-component APCS Acute-phase response P02743
0.587 1.28E−03 Fibrinogen alpha chain FGA Blood clotting/associated with infection P02671
0.566 2.10E−03 Complement component C6 C6 Complement activation P13671
0.512 6.27E−03 Alpha-1-antichymotrypsin SERPINA3 Acute-phase response P01011
0.459 1.60E−02 Haptoglobin HP Acute-phase response P00738
0.413 3.21E−02 Alpha-1-acid glycoprotein 1 ORM1 Acute-phase response P02763
0.405 3.59E−02 Fibrinogen beta chain FGB Blood clotting/associated with infection P02675
0.389 4.51E−02 Neutrophil defensin 3 DEFA3 Antibacterial activities P59666
−0.389 4.48E−02 Complement C1q subunit C C1QC Complement system P02747
−0.423 2.81E−02 Plasma kallikrein KLKB1 Convert prorenin into renin P03952
−0.450 3.14E−02 Flavin reductase (NADPH) BLVRB Oxidoreductase P30043
−0.458 1.63E−02 Clusterin CLU Inhibitor of complement P10909
−0.484 1.05E−02 Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2 Protease inhibitor P19823
−0.509 6.73E−03 Apolipoprotein M APOM Cholesterol homeostasis O95445
−0.751 6.41E−06 Alpha-2-macroglobulin A2M Inhibitor of complement P01023October 2020 | Volume 11 | Article 578505
Bennike et al. Ontogeny of Newborn Plasma Proteomecompared to DOL0. Highly similar changes were seen in the
validation cohort (Supplementary Tables 8, 9).
While the trajectories of C1q chain B and C demonstrated a
similar increase, only C1qB was significantly increased at DOL7
with C1qC at near significance levels (p-value 0.026, q-value
0.060). C1q is predominantly synthesized by blood-cells, whereas
C1r and C1s, like most complement components, are synthesized
mainly by hepatocytes (58). The difference in synthesis location
likely explains the slightly different abundance pattern of C1q
lacking a significant increase on DOL3. The increased concentration
of C1q is in good agreement with previous reports (5). Our study is
the first to report the increased concentration of the individual B
and C subunits.
Our findings demonstrate the increased levels of the
components activating the classical complement pathway,
which is supported by the finding of increasing levels of C4B
rather than C4A. In humans, C4 exists in isotypes A and B, and
following activation of the C1 complex, both isotypes are cleaved
into alpha and beta-chains (59). C4A beta forms an amide bond
which has good efficiency in binding amino group-rich immune
complexes whereas C4B beta forms an ester bond which has
good efficiency in binding carbohydrate-rich cellular surfacesFrontiers in Immunology | www.frontiersin.org 8(60). This makes C4B the more functionally active isotype to
activate C3 through the classical- and lectin pathway (61). As a
result, a deficiency of C4B increases vulnerability to bacterial and
viral infections, whereas C4A deficiency is linked to autoimmune
diseases (61).
Overall, the average plasma concentration of classical
pathway components was significantly increased over the first
week of life, and as early as 24 h after birth.
The Lectin Complement Pathway
Components Decrease Over the First
Week of Life
In contrast to the increase in components of the classical
complement pathway, plasma concentrations of complement
components involved in initiating the lectin complement
pathway decrease over the first week of life. The lectin pathway
is initiated by binding of mannose-binding lectin (MBL),
collectin 11, and ficolins (FCN1, FCN2, and FCN3) to
oligosaccharides and acetylated residues on the surface of
bacteria, viruses, and dying cells. Following binding, mannan-
binding lectin serine protease 1 (MASP-1) or 2 is recruited into
the MBL complex, which similarly to the classical complementA B C
FIGURE 5 | Analysis of protein-protein interactions of the differentiating proteins at (A) DOL1, (B) DOL3, and (C) DOL7 compared to DOL0 (at birth). SAA1 which
was regulated at DOL1 only is indicated with an arrow, and lines indicate interacting proteins. Proteins tagged as complement system in Gene Ontology are
indicated with black boxes without further curation.October 2020 | Volume 11 | Article 578505
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C4bC2b complex. MASP-1 is required for activation of MASP-2,
and of the two only MASP-2 can cleave C4 (62). The resulting
C4bC2b complex triggers the enzymatic cleavage of C3 into C3a
and C3b, and initiates the terminal complement pathway (62).
Of the six lectin complement pathway pattern-recognition
proteins, we identified three in our plasma proteomics dataset:
FCN-2, FCN-3, and MASP1. While the data sufficed for the
identification of MASP1, they did not meet our stringent
requirements for robust quantification, i.e., quantitative
analysis of MASP1 was omitted. FCN-3 showed a downward
trend during the first week of life and was significantly reduced at
DOL7 (Figure 7B) in the main cohort, whereas the reduced
levels at DOL7 were not statistically significant in the validation
cohort (Supplementary Table 10). Since neither of the two
underlying genes are transcribed/translated in blood cells, no
corresponding mRNA information was obtained (63). The lack
of feasibility to detect and/or solidly quantify lectin complement
pathway proteins, might be explained by a presumed low plasma
concentration, and warrants targeted follow-up studies.
Serum concentrations of lectin pathway factors FCN-1, FCN-2,
FCN-3, MASP-2 (64), and MBL (65, 66) are reportedly low in
newborns compared to infants, children, and adults (67). Ficolins
are reportedly lower in neonates than in older children (68). This
is the first study to report on the FCN-3 concentration trajectory
during the first week of life. The measured decreased plasma
concentrations of FCN-3 through the first week of life would
be expected to further be associated with impaired activation
of the lectin complement pathway in early life, and indicates that
the increase of lectin pathway component levels takes place after
the first week of life.
Overall, our findings indicate that the levels of activating
components in the lectin complement pathway remain relatively
deficient in the first week of life, a finding supported by negligible
protein synthesis.
The Alternative Complement Pathway
Components Display a Binomial
Distribution
Compared to classical- and lectin complement pathways,
changes in components of the alternative complement pathwayFrontiers in Immunology | www.frontiersin.org 9displayed a binomial distribution. Our plasma proteomic
workflow provided us with identification and quantification of
three proteins associated with activation of the alternative
complement pathway (69) (Figure 7C). We measured a
statistically significant decrease of properdin (aka complement
factor P/CFP) at DOL7, and an overall decreasing trend during
the first week of life, whereas complement factor B (CFB)
continuously increased from DOL1 onward to DOL7. A
similar protein trajectory was found in the validation cohort
for CFB, whereas the levels of CFP did not achieve statistical
significance (Supplementary Table 9).
CFB and CFP are essential for activation of the alternative
complement pathway, and newborns have reduced plasma
concentration compared to adults (5). Adult levels of CFB are
reportedly achieved within 6 months after birth, in contrast to
CFP-levels that remain low at 6 months of age (5). Here we
demonstrated for the first time that these trajectories are
established as early as 24 h after birth. CFP is the only
complement regulator that enhances complement activation,
by stabilizing the C3bBb-complex. It is mainly synthesized
outside the liver by neutrophils, monocytes, and primary T cells,
and can be secreted upon stimulation (70, 71). The CFP mRNA
levels did not show any significant change during the first week of
life (fold-change < 0.2, p-value > 0.05) (7), indicating insufficient
CFP synthesis to maintain the DOL0-plasma levels, a lack of
compensatory protein synthesis, and a presumed absence of
leukocyte stimulation.
Overall, our findings indicate that the levels of activating
components in the alternative complement pathway remain low
with negligible synthesis in the first week of life.The Terminal Complement Pathway
Components Increase Over the First
Week of Life
The MAC is the terminal point of the terminal complement
pathway and complement activation, and the transmembrane
pore-structure which causes cell lysis and ultimately cell death (54).
Our plasma platform allowed us, for the first time, to quantify
all major MAC components, C5-9 (Figure 7D). At DOL3 and
DOL7, all but one of the major components of MAC showed
significant abundance increases (C5, C6, C8, and C9). The
notable exception was C7, which showed a significant decrease
in plasma levels during the first week of life. Again, similar
protein trajectories were found in the validation cohort
(Supplementary Table 9).
The MAC components are mainly synthesized by hepatocytes.
In this regard, C7 is unique in being synthesized by blood cells
in addition to hepatocytes (72–74). Newborns demonstrate
near-adult levels of C7, as opposed to low levels of the remainder
of MAC components (5, 75). C7 is often the rate-limiting step in
MAC-formation and a decrease of C7 would potentially inhibit
MAC formation, while local C7 synthesis at the site of
inflammation might enhance MAC formation (72). The decrease
of C7 from DOL3 onward is also noteworthy as we were unable to
even detect the corresponding mRNA in whole blood.FIGURE 6 | Simplified scheme of the three activation- and terminal
complement pathway. Inhibitors in blue italic.October 2020 | Volume 11 | Article 578505
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their increase, apart from C7, could indicate MAC maturation to
support innate immunity.
The Complement Inhibitors
Inhibitors are central in controlling complement system activity
in order to limit damage to the site of inflammation and protect
healthy host-cells.
Out of the 10 complement system inhibitors identified in our
analysis, A2M was reduced on DOL1. From DOL1 onward, five
showed a subsequent increase (Figure 7E) based on adjusted
(CLU, vitamin K-dependent protein S/PROS1, and C4b-binding
protein alpha-chain/C4BPA) or unadjusted (CFH andFrontiers in Immunology | www.frontiersin.org 10vitronectin/VTN) p-values at DOL7 compared to DOL0. A
similar trajectory of PROS1, C4BPA, and CFH was seen in the
validation cohort (Supplementary Table 9).
The general decrease of complement inhibitors 24 h after
birth supports our finding of an acute phase response on DOL1,
driven by an increase of acute phase proteins and complement
proteins, and the decrease of several complement system
inhibitors. A2M is a protease inhibitor and it has been
reported that A2M binds covalently to and inhibits MASP
(73), although the inhibitory functions of A2M on the
complement system are still debated (74). In our study the
decreased A2M-levels at DOL1 returned to baseline levels at
DOL3. This is the first study to report on the A2M levels in theTABLE 2 | Change of central complement system proteins at DOL-1, 3, and 7 (0% equals no change relative to at birth).
Protein names GN DOL1 DOL3 DOL7 Protein level Function UPID
Complement C1q subcomponent B C1QB −1.3% 13.7% 34.7% C P02746
Complement C1q subcomponent C C1QC 6.2% 18.9% 26.0% C P02747
Complement C1r subcomponent C1R 12.4% 37.1% 30.6% C P00736
Complement C1s subcomponent C1S 4.1% 22.1% 24.1% C P09871
Complement C2 C2 12.9% 18.5% 18.3% C P06681
Complement C3 C3 4.1% 2.3% 7.4% C, L, A P01024
Complement C4-B C4B 6.7% 32.1% 22.7% C P0C0L5
Complement factor B CFB 27.4% 50.5% 63.1% A P00751
Complement factor D CFD −16.8% −17.7% −20.2% A P00746
Properdin CFP 9.6% −15.7% −31.0% A P27918
Prothrombin F2 −1.0% 7.8% 2.6% C, L, A P00734
Ficolin-2 FCN2 −28.7% −1.5% −21.5% L Q15485
Ficolin-3 FCN3 −20.7% −43.5% −46.5% L O75636
Complement C5 C5 6.6% 26.4% 18.8% MAC P01031
Complement component C6 C6 69.7% 28.8% 23.3% MAC P13671
Complement component C7 C7 3.5% −12.1% −28.3% MAC P10643
Complement component C8 alpha C8A 11.2% 46.4% 72.9% MAC P07357
Complement component C8 beta C8B 22.0% 37.4% 53.6% MAC P07358
Complement component C8 gamma C8G 49.9% 113.2% 162.0% MAC P07360
Complement component C9 C9 75.8% 115.2% 253.2% MAC P02748
Alpha-2-macroglobulin A2M −5.8% −1.3% 0.5% I P01023
C4b-binding protein alpha chain C4BPA 1.8% 17.3% 44.8% I P04003
Complement factor H CFH −4.7% 0.3% 10.9% I P08603
Complement factor I CFI 2.7% −3.9% 14.1% I P05156
Clusterin CLU −12.9% 5.8% 29.5% I P10909
Carboxypeptidase B2 CPB2 −4.0% −0.5% 4.2% I Q96IY4
Carboxypeptidase N catalytic chain CPN1 22.8% 0.3% −1.2% I P15169
Vitamin K-dependent protein S PROS1 −6.1% 21.2% 26.4% I P07225
Plasma protease C1 inhibitor SERPING1 −10.2% 8.2% −25.9% I P05155
Vitronectin VTN −5.7% 0.9% 13.5% I P04004October 2020 | Volume 11 | ArticleGray italic: p-value > 0.05, black: p-value < 0.05, black bold: q-value < 0.05. Trend marker red (blue): positive (negative) change compared to DOL0. Pathways from Gene Ontology without
further curation: C, classical; L, lectin; A, alternative; I, complement inhibitor; MAC, membrane attack complex.578505
Bennike et al. Ontogeny of Newborn Plasma Proteomefirst week of life, and reportedly infants and children have
increased A2M-levels compared to adults, indicating that the
increased trajectory of A2M likely continues past DOL7 (42).
CLU and VTN inhibit formation of the MAC (76), and
newborns have lower levels when compared to adults (42, 77).
The increased MAC inhibitor and the increasing abundances of
the MAC components therefore clearly indicate a readying of the
MAC for the postnatal period during the first week of life.
Newborns have low levels of CFH compared to adults (5), and
the steady levels of CFH and sudden increase at DOL7 could
indicate the early preparation for the alternative complement
pathway, in line with the detected increase of CFB at DOL7
(Supplementary Table 9).
The function of PROS1 in the complement system remains
incompletely understood. However, PROS1 has been suggested
to redirect C4BP to the surface of apoptotic cells to control
activation of the classical complement pathway. PROS1 has high
affinity for negatively charged phospholipid phosphatidylserine,
which is expressed and exposed on cells in the initial stage of
apoptosis. In human plasma, 60–70% of PROS1 circulates bound
in a complex with C4B. It is reported that PROS1 mediates
binding of C4BP to apoptotic cells, thereby controlling
complement activation (78). Newborn levels of PROS1 and
C4BP are lower than adult levels (78). PROS1 also has
anticoagulant effects lost upon binding to C4BP. The similar
increase of PROS1 and C4BP makes it possible that the increasedFrontiers in Immunology | www.frontiersin.org 11level of PROS1 is related to regulating the increase of
complement system components. However, further studies
are required.
Altogether, our findings demonstrated the consistent and robust
increase of complement components in the classical activation
pathway over the first week of life, while components of the
lectin- and alternative pathway lacked a clear developmental
trajectory. Additionally, all components of the MAC except the
rate-limiting C7 were increased at DOL7. The absence of blood cell
expression of C7, SAA1, and CFP indicates that blood cell
stimulation is not a main initiator of the protein synthesis in the
first week of life, and that the maturation of the complement
components is therefore mainly driven by ontogeny rather than
bacterial stimulation. Finally, we measured a decrease of most
complement system inhibitors at DOL1 and subsequent recovery
and increase at DOL7. Newborns are deficient in most complement
components and the increasing plasma-levels indicate that the
complement system components are approaching adult levels and
maturation. However, future studies should be performed to
investigate if the complement system activity follows the
measured concentrations of complement system components.
Speculatively, the apparent prioritization of synthesis of
components related to the classical and terminal complement
pathway, could be a means of obtaining a first complete
complement response to pathogens as quickly as possible during
a resource constrained immune system development.A B
D E
C
FIGURE 7 | Average change of complement proteins grouped by their function across the first week of life compared to DOL0. (A) classical pathway, (B) lectin
pathway, and (C) alternative pathway. (D) Membrane attack complex (MAC) proteins, (E) complement inhibitors. Pathway activations from Gene Ontology without
further curation.October 2020 | Volume 11 | Article 578505
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the Complement System Poorly Reflect
Protein Plasma Levels
The inconsistency between protein and mRNA levels for several
complement components, led us to perform a correlation
analysis for the complement pathway data. We extracted all
complement proteins for which we had corresponding whole
blood mRNA information.
While the majority of the complement proteins with
corresponding whole blood transcripts increased with age
(Figure 8), the corresponding mRNA levels had a binominal
distribution, with one group increasing from DOL0 to DOL3 and
subsequent leveling off at DOL7, while the other group showing
little abundance differences during the first week of life (Figure 8).
Accordingly, there was a weak correlation between the change in
protein plasma levels and change in whole blood mRNA levels (all
pairs R < 0.3, p-value > 0.05). Of note, when we performed the
correlation analysis using DOL average rather than individual
participant data, we achieved much higher (R −0.67 to 0.88) yet
still statistically insignificant (p-value > 0.05) correlation
coefficients. This observation suggests large protein-to-RNA
level variations between participants, or could represent
concordance of mRNA and protein level data for only a small
subset of complement protein. Indeed, of the 30 monitored
complement proteins, the mRNA levels reflected the protein
level changes for the following seven complement proteins
(average R > 0.3): C1QB (R = 0.88), C1QC (R = 0.86), C2
(R = 0.90), C3 (R = 0.85), CLU (R = 0.74), SERPING1
(R = 0.79), and complement factor D/CFD (R = 0.49).
Differences between the mRNA/transcriptomics and
proteins/proteomics information highlight the fact that there is
no transcriptomics equivalent to the plasma proteome. The
plasma proteome is a systemic body fluid integrating protein
reflecting dynamic processes of protein expression and degradation
across different organ systems and body compartments, while the
whole blood transcriptome provides transcriptomic information
from whole white blood cell fraction only (non-nucleated red blood
cells having proteins but no transcripts), with neutrophils having
lower transcript abundance making a more minor contribution. As
the white blood cells are removed during the plasma preparation,
whole blood transcriptomics and plasma proteomics map the two
complementary, mutually exclusive blood fractions. Indeed,
integration of the transcriptome and proteome is key to elucidate
meaningful physiologic changes and generate mechanistic
hypotheses to study the immune ontogeny of the newborn.Increased Immunoglobulin M and J Chain
Synthesis
The increased levels of components related to the classical
complement activation pathway prompted us to investigate
IgM and IgG, the main target molecules for the C1-complex
and thereby activators of the classical complement pathway. IgM
cannot cross the placental barrier and is the first antibody
synthesized by peripheral blood lymphocytes during primary
infections, thereby highlighting its central role in the initialFrontiers in Immunology | www.frontiersin.org 12immune response (79, 80). IgM is a pentamer connected with
joining chains (J chain), which regulates the polymerization of
the molecule for efficient secretion (79, 81).
Plasma levels of IgM increased over the first week of life
(Figure 9A), a finding confirmed in the validation cohort
(Supplementary Figures 6A, B). J chain levels also increased,
mirroring the IgM concentration trajectories (Figure 9B), with a
strong positive Pearson’s correlation that was statistically
significant (R = 0.73, p-value = 2.44E−5). In accordance with
plasma concentrations, we measured similar increased mRNA
level trajectories for the IgM and J chain when compared to the
plasma proteins and found a significant positive correlation
between plasma and mRNA levels (Figures 9A, B dotted line).
The physiologic average serum level of IgM is reportedly
18.5 mg/dl (15% of adult levels) in the first month of life, and this
increases 3-fold in months 1–5 of life reaching adult levels by 1–
2 years of age (82). The present study demonstrated that IgM
levels increased from DOL3 onward in the first week of life, and
based on the data an incant at DOL7 can be expected to have IgM
concentrations of 38 to 54 mg/dl, when assuming average IgM
concentrations at DOL0. J chain is required for Ig-transport
across the mucosal epithelium, e.g., for secretion. Whether J chain
regulation occurs at the protein level remains to be determined,
and there are conflicting views on the origins of some of the
J chain secreting cells (81). Based on our findings, there was
J chain expression in whole blood and there were ontogeny-
induced increases at both the cell transcriptional and plasma-
protein levels.
Insufficient Immunoglobulin G Synthesis
IgG antibodies are the most abundant Ig-class in the circulation,
especially in the fetus through placental transfer mediated by the
FcRn receptors (82). Placentally transferred IgG provide
protection in the first weeks of life due to the relatively long in
vivo half-life of IgG (~3 weeks) (83). Of the four IgG subclasses,
IgG1 can primarily be induced by soluble protein antigens and
membrane proteins, IgG2 by bacterial capsular polysaccharides,
IgG3 by viral antigens (like IgG1) and induce pro-inflammatory
effects, and IgG4 by repeated exposure to a non-infectious
antigen (84).
We measured significantly decreasing plasma concentrations
of all four IgG subclasses over the first week of life, and IgG1 was
significantly decreasing as early as 24 h after birth (Figures 9C,
10A–D). A similar trajectory of IgG plasma-levels was seen in
the validation cohort (Supplementary Figures 7A–D).
Serum levels of IgG1-4 are reportedly decreased in 1–5 month
old infants compared to 0–30 day old newborns (82). Our study
adds to the existing literature by providing granularity in the
IgG1-4 plasma level trajectory over the first week of life. The
measured decreases in IgG levels from birth to 5 months of age
are consistent with a drop of maternal IgG levels in the newborn
circulation, on top of low endogenous production. This
physiologic transient hypogammaglobulinemia is a well-described
phenomenon and is typically not clinically significant. Adult
concentrations of most IgG-subclasses are eventually reached by
4–6 years of age (82).October 2020 | Volume 11 | Article 578505
Bennike et al. Ontogeny of Newborn Plasma ProteomeWe were interested in determining the timing of initiation for
endogenous IgG synthesis from newborn plasma cells. We thus
measured mRNA levels of IgG subclasses from DOL0, and found
IGHG1 mRNA transcripts in 26 of the 30 newborns at DOL0
(validation cohort 13 of 19 newborns), indicative of endogenous
IgG1 synthesis as early as DOL0. Additionally, we observed that
IGHG1 mRNA levels were significantly increased on DOL3 and
DOL7 (Figure 9C), while no mRNA was detected for IGHG2-4
in either cohort. The protein levels and mRNA levels of IGHG1
were negatively correlated (R = −0.42, p-value = 0.037),
indicating that despite endogenous IgG1 synthesis as early as
DOL0, plasma levels decreased over the first week of life, likely
because of dominance of the in vivo degradation process. These
findings were reproduced in the validation cohort (Supplementary
Figure 6C).
To investigate the impact of the IgG1 synthesis on the plasma
concentration, we calculated the apparent IgG1 plasma
concentration half-time in our dataset to 21.1 days. This is
comparable to the reported IgG1 in vivo half-life of 21–
25.8 days (85, 86). The decline in IgG1 plasma concentration
in newborns is thereby explained by the reported IgG1 in vivo
half-life (with no synthesis). This demonstrates that IgG1
synthesis remains insignificant in the first week of life.
We performed an analysis of the inter IgG-subclass ratios. As
different proteins were compared, we estimated the IgG-subclass
abundances using intensity-based absolute quantitation (iBAQ)
values. To enable a comparison to adult levels, we included data
from a previously published proteomics study of plasma from 30
healthy adult Danes (10). To compensate for the different
experimental designs, we normalized the IgG ratios to
IgG2 in each dataset. Of note, normalization to IgG3 yielded
similar results.
The analysis revealed that IgG1 was the most abundant IgG
throughout the first week of life followed by IgG2, IgG3, and
IgG4 (Figures 10E, F), in agreement with published literature
from newborns within the first 30 days of life (82).Frontiers in Immunology | www.frontiersin.org 13Of the four IgG subclasses, there is a preferential placental
transport of IgG1, followed by IgG4, and to a lesser extend of
IgG3 and IgG2, based on FcRn receptor affinity (55, 87). Healthy
term newborns are born with similar to increased IgG-
concentrations compared to the mother (88). Because we did
not have access to the maternal IgG-levels, we obtained a
previously published proteomics dataset of plasma from 30
healthy adult Danes (Figures 10E, F). Newborns had a
significantly increased IgG1 to IgG2-4 ratio, when compared to
adults. The findings were reproduced in the validation cohort
(Supplementary Figures 7E, F).
IgM, IgG1, and IgG3 antibodies are efficient activators of the
complement system through the classical pathway, whereas a
high epitope density is needed of IgG2, and IgG4 is ineffective
(89, 90). The relatively elevated concentration of IgG1 in the
newborns compared to adults, combined with the specific
synthesis of this subclass, and the increase in IgM, suggest a
central role of the classical pathway of complement activation for
newborn immunity.CONCLUSION
Our study presented a mapping of the plasma proteome across the
first week of human life in a paired African cohort with an
independent geographically distinct validation cohort in
Australasia. Newborns are primarily dependent on innate
immunity to shield them from infection, and we characterized
the ontogeny of several innate immune components over the first
week of life. Specifically, we found increased plasma and mRNA
levels of all major components related to the classical and terminal
complement pathways, including the C1 complex and the target
molecule IgM, as early as 24 h after birth. All components of the
MAC, except C7 which is at near-adult levels at birth, increased by
DOL7, as well as most complement system inhibitors, suggesting a
central role for the classical complement pathway for neonatalFIGURE 8 | Divergence of complement plasma protein and whole blood messenger RNA (mRNA) levels, as compared to DOL0, of the 11 complement proteins
with detected whole blood mRNA.October 2020 | Volume 11 | Article 578505
Bennike et al. Ontogeny of Newborn Plasma Proteomeimmunitysuggesting a central role for the classical complement
pathway for neonatal immunity (91–93). With respect to
complement components, we noted significant differencesFrontiers in Immunology | www.frontiersin.org 14between plasma protein concentrations and whole blood mRNA
counts, highlighting the value of multi-OMICS integration to gain
biologic insights and generate well-informed hypotheses.A B C
FIGURE 9 | Protein and messenger RNA (mRNA) levels (dotted line) of (A) IgM, (B) J chain, (C) IgG1 across the first week of life compared to DOL0, with mean
abundance difference indicated by dots connected by lines. Protein to RNA correlation and p-value given. Statistics compared to DOL0: q-value protein (mRNA)
<0.05: *(*), <0.01: **(**), <0.001: ***(***).A B
D
E
FC
FIGURE 10 | Protein levels of (A–D) IgG1-4 across the first week of life as compared to DOL0, with mean abundance difference indicated by dots connected by
solid line. (E) Comparison of the ratios of IgG1-4 normalized to IgG2 between adult-levels (purple) and newborn-levels at DOL0 (gray), or (F) DOL7 (blue). Statistics
A–D (E, F): q-value <0.05: *, <0.01: **, <0.001: ***.October 2020 | Volume 11 | Article 578505
Bennike et al. Ontogeny of Newborn Plasma ProteomeWe were able to provide granularity around the trajectory of
different immunoglobulin subtypes during the first week of life.
We detected endogenous synthesis of the IgG1 isotype, but not
IgG2-4 and the ratio of IgG1 to IgG2-4 was elevated compared to
adults, highlighting the importance of IgG1 for early immunity.
Levels of the maternally transferred IgG1-4 declined over the first
week of life. We also detected an acute phase response
accompanied by a surge in levels of acute phase proteins on
the first day of life and an overall reduction of inhibitors. The
functional consequences of the differences between the
timepoints could not be assessed in vitro due to sample size
restrictions, and should be investigated in further studies.
Additionally, studies involving a higher number of samples,
pairing with maternal samples, and higher time resolutions are
needed to identify the drivers of this response.
The main strength of our study is the performance of deep
proteomics analysis with small volumes of blood plasma. Even
though most of our findings are not surprising, this study’s main
contribution to the literature is a new conceptual framework of
neonatal immune ontogeny based on a consistent developmental
trajectory of the newborn’s immune system over the first week of
human life across continents, as evidenced by highly similar
trajectories in two geographically distinct newborn cohorts. This
study is also proof of concept that high quality, reproducible
systems biology research is feasible even in low resource settings.
In summary, our findings have shed additional light on
functionally distinct immunobiological processes occurring in
the human neonate during the first week of life and can serve as a
crucial overview and hypothesis-generating resource for
researchers in the field of immune ontogeny. Interpretation of
our observations in the context of perinatal physiology will be
key to understanding the delicately balanced regulation of the
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et al. Complement alternative pathway acts as a positive feedback
amplification of neutrophil activation. Blood (2011) 117(4):1340–9. doi:
10.1182/blood-2010-05-283564
71. Wirthmueller U, Dewald B, Thelen M, Schäfer MK, Stover C, Whaley K, et al.
Properdin, a positive regulator of complement activation, is released from
secondary granules of stimulated peripheral blood neutrophils. J Immunol
Baltim Md 1950 (1997) 158(9):4444–51.
72. Lachmann PJ, Thompson RA. Reactive lysis: the complement-mediated lysis
of unsensitized cells. II. The characterization of activated reactor as C56 and
the participation of C8 and C9. J Exp Med (1970) 131(4):643–57. doi: 10.1084/
jem.131.4.643
73. Terai I, Kobayashi K, Matsushita M, Fujita T, Matsuno K. alpha 2-
Macroglobulin binds to and inhibits mannose-binding protein-associated
serine protease. Int Immunol (1995) 7(10):1579–84. doi: 10.1093/intimm/
7.10.1579
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